Controlled Release Magnesium Threonate Composition for Reduced GI Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The majority of the American population has magnesium deficiency due to inadequate dietary intake, and existing magnesium supplements have low absorption rates, leading to adverse effects like diarrhea and insufficient magnesium levels in the body.

Innovation Solution

A controlled release magnesium composition comprising magnesium and threonate, which is formulated to provide a slow and sustained absorption profile, reducing gastrointestinal adverse effects and increasing bioavailability, thereby maintaining therapeutic magnesium levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If high dose magnesium supplement is administered to reach recommended daily allowance, then magnesium intake is sufficient, but gastrointestinal adverse effects like diarrhea occur

Engineering Contradiction:

Improvemagnesium intakeVSAvoidgastrointestinal adverse effects

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent divides the magnesium supplement into multiple dosage units (capsules) that can be taken throughout the day, segmenting the total daily dose into smaller portions to reduce gastrointestinal burden while achieving the required magnesium intake

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent provides flexible dosing regimens that can be adjusted based on individual needs and tolerance, allowing dynamic modification of dosage amount and frequency to optimize magnesium absorption while minimizing adverse effects

Inventive Principle:

Principle #15Dynamics

2Quantity of substance

If conventional magnesium supplements are used, then magnesium is provided, but absorption rate is low (≤40%)

Engineering Contradiction:

Improvemagnesium absorptionVSAvoidabsorption rate

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent changes the chemical form of magnesium from conventional salts (oxide, carbonate) to chelated forms (citrate, glycinate, malate, orotate) that have higher solubility and bioavailability, thereby improving absorption rate while maintaining effective magnesium delivery

Inventive Principle:

Principle #35Parameter changes

3Ease of manufacture

If magnesium oxide is used as supplement, then it is widely available and inexpensive, but absorption rate is only about 4%

Engineering Contradiction:

Improveavailability and costVSAvoidabsorption rate

Core Design Contradiction:

Ease of manufactureVSProductivity

Solution Approach 1:

The patent uses composite chelated magnesium compounds where magnesium is bound to organic ligands (citrate, glycinate, etc.), creating materials that combine the benefits of high magnesium content with improved bioavailability and absorption characteristics

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS8734855B2Slow release magnesium composition and uses thereof

Publication Date: 2014.05.27 NEUROCENTRIA INC

AI summary

The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.